SCHEMBL16615958

SCHEMBL16615958

Cc1ncc(CNC(=O)c2cnc(CNS(=O)(=O)c3cccc(Cl)c3)c(C)n2)s1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.77
GRIN1 Q05586 2/20 0.77
GRIN2B Q13224 1/20 0.77
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 4/20 0.40
PKM P14618 1/20 0.40
HSD11B1 P28845 6/20 0.40
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
FBP1 P09467 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
EDNRB P24530 1/20 0.37
EDNRA P25101 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615955 0.91 GRIN2A (0.76) GRIN2AGRIN1GRIN2BSMN1; SMN2PIK3CA
SCHEMBL16615950 0.89 GRIN2A (0.78) GRIN2AGRIN1GRIN2BPIK3CDPIK3CA
SCHEMBL16598208 0.88 GRIN2A (0.85) GRIN2AGRIN1GRIN2BHSD11B1PIK3CA
SCHEMBL30151536 0.87 GRIN2A (1.00) GRIN2AGRIN1GRIN2BALDH1A1PIK3CD
SCHEMBL16615815 0.87 GRIN2A (1.00) GRIN2AGRIN1GRIN2BALDH1A1PIK3CD
SCHEMBL16615959 0.86 GRIN2A (0.85) GRIN2AGRIN1GRIN2BALDH1A1PIK3CD
SCHEMBL16615832 0.86 GRIN2A (0.78) GRIN2AGRIN1GRIN2BSMN1; SMN2ALDH1A1
SCHEMBL16615921 0.85 GRIN2A (0.75) GRIN2AGRIN1GRIN2BSMN1; SMN2LMNA
SCHEMBL16598435 0.85 GRIN2A (0.61) GRIN2AGRIN1GRIN2BSMN1; SMN2ALDH1A1
SCHEMBL16615960 0.84 GRIN2A (0.82) GRIN2AGRIN1GRIN2BALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US claimed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.